Objectives: To provide early data regarding clinical utility of dabigatran in Al-Ain, United
Arab Emirates (UAE). Methods: This was an ethics approved retrospective cross sectional …

Background Dabigatran etexilate is an oral anticoagulant. It was added to our hospital's
formulary in 2010 for the indications of thromboprophylaxis in adult patients following total …

Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over
warfarin such as no need for routine monitoring and fewer drug interactions. This drug was …

Background Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed
to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation …

ABSTRACT Background: Direct oral anticoagulants (DOACs) especially dabigatran, have
gain popularity for their efficacy, fixed dosing and favourable safety profile. A dabigatran …

Background Establishment of thromboembolism prevention remains a challenge despite the
widespread consensus that thromboprophylaxis safely reduces patient morbidity and …

Background The incidence of thromboembolic events in patients on dabigratran is low
compared to warfarin, but the consequences of these events can be catastrophic. Monitoring …

Background: During its commercialization phase, unprecedented effects of new
medicaments can be discovered. Dabigatran is an anticoagulant approved by Brazilian …

Background: Few data exist to evaluate the use of dabigatran among hospitalized patients
and this population that may be at increased risk for toxicity or reduced efficacy. As such, the …

Dabigatran etexilate, an oral direct thrombin inhibitor, was approved by the Food and Drug
Administration to reduce the risk of stroke and systemic embolism in patients with …